European Commission logo
English English
CORDIS - EU research results

Article Category

Content archived on 2023-03-23

Article available in the following languages:


HumEn: New EU research grant focused on stem cell-based treatment of Diabetes

A grant of 6 million euros for the HumEn project brings together leading European stem cell-research groups and industrial partners in a coordinated and collaborative effort aimed at developing glucose-responsive, insulin-producing beta cells for future cell-replacement therapy in diabetes.

The project will contribute significantly to better treatment and quality of life for the increasing population of diabetics. The HumEn project, supported through the European Commission’s HEALTH research programme and headed by Professor Henrik Semb from the Danish Stem Cell Center (DanStem) at the University of Copenhagen, strengthens the future perspectives for cell based treatment of diabetes. The project is important for keeping Europe on the forefront of stem cell research, creating new commercial possibilities and increased competitiveness for the European biomedical industry. The grant is for four years. BEST STEM CELL RESEARCHERS IN A UNIQUE, COORDINATED EFFORT Despite progress in creating insulin-producing beta cells from human pluripotent stem cells, full maturation into transplantable beta cells that can cure diabetes has so far not been achieved in the laboratory. - The mechanisms controlling the maturation of human pluripotent stem cells towards insulin-producing beta cells are extremely complex, explains head of project, Professor Henrik Semb, - But with this grant, we are able to bring together some of the best stem cell research groups in Europe. I believe that HumEn’s unique constellation of research competences, the interdisciplinarity, and the very coordinated and collaborative approach that our project is based on, will enable us to reach the goal of developing functional, glucose-responsive, insulin-producing beta cells, and thus bring the new therapy closer to the patients. All partners, six academic and three industrial, contribute state-of-the art expertise in complementary research areas including beta cell development and physiology, beta cell transplantation, human pluripotent stem cell biology, polymer chemistry, niche engineering, and epigenetics. HumEn IS PART OF LARGER, EUROPEAN EFFORT The European Commission’s FP7 HEALTH research programme recently granted funding for seven stem cell research projects. Common for these projects is the focus on understanding the underlying mechanism of the self-renewing capacity of stem cells and their differentiation into mature functional cell types suitable for various cell-based therapeutic applications. HumEn has already established closer, collaborative relations to three of the other projects. The four consortia will collaborate and coordinate training and outreach activities, sharing relevant basic knowledge and benefit from interdisciplinary and intersectorial synergies across the projects. The three other projects are: PluriMes, a project focused on directing pluripotent stem cells to become bone and muscle forming cells; Neurostemcellrepair, a project aimed at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders such as Parkinson's Disease; and ThymiStem, a program to develop stem cell approaches to boosting the immune system by repairing the thymus, a key organ for producing important immune cells.


Austria, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, United Kingdom